Funds · 13F filer · Foster City, CA

Gilead Sciences, Inc.

$1.6B in 5 U.S. stocks and ETFs at the end of June 30, 2026, as reported to the SEC.1

1y return+60.5%S&P 500 +20.9%

These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.

$100 invested in its stock picks

Since December 31, 2024: $132 against $127 in the S&P 500.2

Gilead Sciences, Inc.S&P 500 (SPY)
$76$100$13820242026

Top holdings

At the end of June 30, 2026. Change is in shares since the quarter before.2

StockValueShare of portfolioChange
RCUSArcus Biosciences Inc.$968.8M58.8%
LKFTLakefront Biotherapeutics$500.2M30.3%
ASMBAssembly Biosciences Inc.$136.8M8.3%+10.5%
KYTXKyverna Therapeutics Inc.$36.8M2.2%
Xilio Therapeutics Inc.CUSIP 98422T100$6.2M0.4%

Best picks still held

How each current holding has done since the quarter it first appeared in its filings (up to six years back).

StockHeld sinceReturn sinceNow worth
KYTXKyverna Therapeutics Inc.December 31, 2024+138.2%$36.8M
RCUSArcus Biosciences Inc.December 31, 2024+107.1%$968.8M
ASMBAssembly Biosciences Inc.December 31, 2024+74.1%$136.8M
LKFTLakefront BiotherapeuticsDecember 31, 2024+9.0%$500.2M

Sold off last quarter

  • Arcellx IncCUSIP 03940C100 was $771.7M

Quarter by quarter

QuarterIts picksS&P 500
June 30, 2026−4.5%+14.8%
March 31, 2026+9.7%−4.6%
December 31, 2025+12.8%+2.4%
September 30, 2025+35.8%+7.8%
June 30, 2025+7.4%+10.5%
March 31, 2025−23.7%−4.6%

Sources

Every number on this page points here. Each one links to the public record.

  1. 1
    CIK 882095
  2. 2
    SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/882095/000112329226001034/
    Filed August 3, 2026 · accession 0001123292-26-001034